In contrast, the M2R-selective antagonist gallamine was without effect on any measure of peripheral neuropathy, which is consistent with its lack of impact on neurite outgrowth from sensory neurons in vitro [41] and the focus of neuroprotective properties to molecules that antagonize the M1R [42,44]. The gene discussed is CHRM1; the disease is peripheral neuropathy.